Institutional Investors
Institutional investors — pension funds, endowments, and family offices — with psychedelic portfolio exposure.
All Organisations
Ark Invest
Ark Invest is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
BTIG
BTIG is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Berenberg
Berenberg is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
BlackRock
BlackRock is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Canaccord Genuity
Canaccord Genuity is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Cantor Fitzgerald
Cantor Fitzgerald is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Cowen
Cowen is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
EF Hutton
EF Hutton is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Evercore
Evercore is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
H.C. Wainwright & Co.
H.C. Wainwright & Co. is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Jefferies
Jefferies is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Johnson & Johnson
Johnson & Johnson is an American multinational healthcare corporation and one of the world's largest pharmaceutical companies, operating its pharmaceutical business through the Janssen subsidiary. Through Janssen, J&J developed and commercialized esketamine nasal spray (Spravato), which received FDA approval in 2019 as the first rapid-acting antidepressant approved in decades.
Maxim Group
Maxim Group is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Morgan Stanley
Morgan Stanley is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Oppenheimer
Oppenheimer is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Orbimed Advisors
Orbimed Advisors is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Otsuka
Otsuka is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Pura Vida Investments
Pura Vida Investments is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Roth Capital
Roth Capital is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.
Stifel
Stifel is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.